23 March 2022 | News
Acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies
image credit- shutterstock
Japan-based FUJIFILM Corporation has announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, will acquire Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed.
Shenandoah Biotechnology is a privately held company located in Warminster, Pennsylvania, that manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility.
The use of cGMP manufactured products smooths the transition of biological therapies from preclinical to clinical phases.
Yutaka Yamaguchi, chairman and chief executive officer, FUJIFILM Irvine Scientific. “Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs. This acquisition will be an important step toward achieving sales target of 100 billion yen in Fujifilm’s Life Sciences Business by FY2025.”